Eyepoint Pharmaceuticals aims to foster new approaches in retina care at Montreal ASRS gathering

Eyepoint Pharmaceuticals aims to foster new approaches in retina care at Montreal ASRS gathering
Eyepoint Pharmaceuticals targets retina advances

Eyepoint Pharmaceuticals is set to participate in the ASRS 44th Annual Meeting in Montreal, focusing on engaging with the retina community to explore innovative strategies for advancing treatments and improving patient outcomes.

The company seeks to connect with industry professionals to exchange ideas and collaborate on initiatives that push the boundaries of current retina care practices.

Eyepoint has previously called for early detection as symptoms of wet age-related macular degeneration progress rapidly, while promoting its clinical trial program. The company is also slated to present new research in retinal disease treatment at CTS Retina 2026 in Las Vegas. These initiatives reflect Eyepoint’s ongoing engagement with developments in retinal science.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.